Key result
Clarithromycin reduces cardiotoxicity in doxorubicin-treated rats by increasing glutathione and decreasing malondialdehyde.
Why the study?
Doxorubicin-induced cardiotoxicity limits its clinical use, and the potential cardioprotective effect of clarithromycin against this toxicity was investigated.
Does clarithromycin prevent doxorubicin-induced cardiac toxicity in rats?
Does clarithromycin prevent doxorubicin-induced cardiac toxicity in rats?
p-value: p=0.025 and 0.022
Clarithromycin demonstrates cardioprotective effects against doxorubicin-induced cardiotoxicity in a rat model by reducing oxidative stress and histopathological damage.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for clarithromycin cardioprotection; leaves open translation to human doxorubicin therapy.
Mustafa Doğan (2014) studied Doxorubicin-induced cardiac toxicity (n=28). Clarithromycin vs. Doxorubicin alone was evaluated on Antioxidant (glutathione) and oxidant (malondialdehyde) levels in cardiac tissue (p=0.025 and 0.022). Clarithromycin significantly increased glutathione (p=0.025) and decreased malondialdehyde (p=0.022) levels, reducing cardiotoxicity in doxorubicin-treated rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: